The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Official Title: A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Study ID: NCT01721746
Brief Summary: The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Mayo Clinic, Phoenix, Arizona, United States
UCSD Moores Cancer Center, La Jolla, California, United States
The Angeles Clinic & Research Institute, Los Angeles, California, United States
University Of California - Los Angeles, Los Angeles, California, United States
San Francisco Oncology Associates, San Francciso, California, United States
UCSF Comprehensive Cancer Center, San Francisco, California, United States
University Of Colorado, Aurora, Colorado, United States
Yale University School Of Medicine, New Haven, Connecticut, United States
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Orlando Health, Inc, Orlando, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Winship Cancer Institute, Atlanta, Georgia, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
University Of Michigan Health System, Ann Arbor, Michigan, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Allina Health, Minneapolis, Minnesota, United States
Washington University School Of Medicine, Saint Louis, Missouri, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
NYU Clinical Cancer Center, New York, New York, United States
MSKCC Clinical Laboratory at Nassau, New York, New York, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States
University Hospitals, Cleveland, Ohio, United States
Providence Oncology And Hematology, Portland, Oregon, United States
Network Office of Research and Innovation, Allentown, Pennsylvania, United States
St. Luke'S Health System, Allentown, Pennsylvania, United States
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Local Institution, Innsbruck, , Austria
Local Institution, Wien, , Austria
Local Institution, Brussels, , Belgium
Local Institution, Bruxelles, , Belgium
Local Institution, Edegem, , Belgium
Local Institution, Leuven, , Belgium
Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil
Local Institution, Rio de Janeiro, , Brazil
Local Institution, Sao Paulo, , Brazil
Cross Cancer Institute, Edmonton, Alberta, Canada
Princess Margaret Hospital, Toronto, Ontario, Canada
CHUM, Montreal, Quebec, Canada
Sir Mortimer B Davis - Jewish General Hospital, Montreal, Quebec, Canada
Aarhus Universitetshospital, Aarhus, , Denmark
Herlev Hospital, Herlev, , Denmark
Odense University Hospital, Odense, , Denmark
Local Institution, Clermont Ferrand, , France
Local Institution, Lille Cedex, , France
Hopital La Timone, Marseille, , France
Local Institution, Nantes Cedex 01, , France
Local Institution, Nice, , France
Local Institution, Paris, , France
Local Institution, Pierre Benite, , France
Local Institution, Villejuif, , France
Local Institution, Wuerzburg, Bayern, Germany
Local Institution, Buxtehude, , Germany
Local Institution, Dresden, , Germany
Local Institution, Essen, , Germany
Local Institution, Frankfurt am Main, , Germany
Local Institution, Hannover, , Germany
Local Institution, Heidelberg, , Germany
Local Institution, Kiel, , Germany
Local Institution, Luebeck, , Germany
Local Institution, Magdeburg, , Germany
Local Institution, Munich, , Germany
Local Institution, Tubingen, , Germany
Local Institution, Jerusalem, , Israel
Local Institution, Ramat Gan, , Israel
Local Institution, Bari, , Italy
Local Institution, Bergamo, , Italy
Local Institution, Genova, , Italy
Local Institution, Milano, , Italy
Local Institution, Milano, , Italy
Local Institution, Napoli, , Italy
Local Institution, Padova, , Italy
Local Institution, Roma, , Italy
Local Institution, Siena, , Italy
Local Institution, Amsterdam, , Netherlands
Local Institution, Groningen, , Netherlands
Local Institution, Maastricht, , Netherlands
Local Institution, Barcelona, , Spain
Local Institution, Barcelona, , Spain
Local Institution, Madrid, , Spain
Local Institution, Madrid, , Spain
Local Institution, Pamplona, , Spain
Local Institution, Valencia, , Spain
Local Institution, Lausanne, , Switzerland
Local Institution, Zuerich, , Switzerland
Local Institution, Manchester, Greater Manchester, United Kingdom
Local Institution, Southampton, Hampshire, United Kingdom
Local Institution, Oxford, Oxfordshire, United Kingdom
Local Institution, Newcastle Upon Tyne, Tyne And Wear, United Kingdom
Local Institution, London, , United Kingdom
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR